Andrea Mella-Torres

Andrea Mella-Torres

Auto-generated profile, based on publicly available information

Andrea Mella-Torres

Centro de Biotecnología Acuícola, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2022 in Canadian Journal of Infectious Diseases and Medical Microbiology
Verified
Journal Article
Open access
PDF file
RLRoberto Luraschi
Roberto Luraschi
CBCarlos Barrera-Avalos
Carlos Barrera-Avalos
EVEva Vallejos-Vidal
Eva Vallejos-Vidal
JAJaviera Alarcón
Javiera Alarcón
AMAndrea Mella-Torres
Andrea Mella-Torres
ASAnamaria Sandino
Anamaria Sandino
The early detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the real-time quantitative polymerase chain reaction (RT-qPCR) as a gold-standard molecular tool has allowed to test and trace the viral spread and the isolation of COVID-19-infected patients. The detection capacity of viral and internal genes is an essential parameter to consider and analyze during the assay. In this study, we analyze the performance of the two commercial RT-qPCR kits used in Chile, TaqMan™ 2019-nCoV Control Kit v1 (Thermo Fisher) and MaxCov19 (TAAG Genetics), for the COVID-19 diagnosis from nasopharyngeal swab samples (NPSs). Our results show a lower sensitivity of the TAAG kit compared to the Thermo Fisher kit, even in the detection of SARS-CoV-2 mutations associated with its variants. This study reinforces the relevance of evaluating the performance of RT-qPCR kits before being used massively since those with lower sensitivity can generate false negatives and produce outbreaks of local infections.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
CBCarlos Barrera-Avalos
Carlos Barrera-Avalos
XDXimena Díaz
Ximena Díaz
BMBastián Madrid
Bastián Madrid
SMSofía A. Michelson
Sofía A. Michelson
CRClaudia Robles-Planells
Claudia Robles-Planells
CAClaudio Acuña-Castillo
Claudio Acuña-Castillo
Active immunotherapy against cancer is based on immune system stimulation, triggering efficient and long‐lasting antigen‐specific immune responses. Immunization strategies using whole dead cells from tumor tissue, containing specific antigens inside, have become a promising approach, providing efficient lymphocyte activation through dendritic cells (DCs). In this work, we generate whole dead tumor cells from CT26, E.G7, and EL4 live tumor cells as antigen sources, which termed immunogenic cell bodies (ICBs), generated by a simple and cost‐efficient starvation‐protocol, in order to determine whether are capable of inducing a transversal anticancer response regardless of the tumor type, in a similar way to what we describe previously with B16 melanoma. We evaluated the anticancer effects of immunization with doses of ICBs in syngeneic murine tumor models. Our results showed that mice’s immunization with ICBs‐E.G7 and ICBs‐CT26 generate 18% and 25% of tumor‐free animals, respectively. On the other hand, all carrying tumor‐animals and immunized with ICBs, including ICBs‐EL4, showed a significant delay in their growth compared to not immunized animals. These effects relate to DCs maturation, cytokine production, increase in CD4+T‐bet+ and CD4+ROR‐γt+ population, and decrease of T regulatory lymphocytes in the spleen. Altogether, our data suggest that whole dead tumor cell‐based cancer immunotherapy generated by a simple starvation protocol is a promising way to develop complementary, innovative, and affordable antitumor therapies in a broad spectrum of tumors.